SCHEDULE: Anson Funds Discloses 7% Stake in Oncolytics Biotech

Anson Funds Management LP and affiliated entities have disclosed a 7% beneficial ownership stake in Oncolytics Biotech, Inc. through a Schedule 13G amendment.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 7,649,050 shares of Oncolytics Biotech, Inc. Common Stock.
• This ownership represents 7% of the outstanding Common Stock of Oncolytics Biotech, Inc.
• The reported shares include Common Stock underlying outstanding warrants held by the Funds, where Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors.
• The beneficial ownership percentage is calculated based on 101,246,187 shares issued and outstanding, plus 7,649,050 shares receivable upon warrant exercise, totaling 108,895,237 shares.
• The warrants held by the reporting persons include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99% of the outstanding Common Stock.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant ownership stake by an investment group, which can be viewed as a positive signal of investor confidence, though it does not contain operational or financial performance data.

Positives

• A significant 7% stake by Anson Funds and its affiliates indicates a notable investment interest in Oncolytics Biotech, Inc.

Risks

• The beneficial ownership limitation on warrants, restricting exercise if it would lead to ownership exceeding 9.99%, could cap the immediate upside for the reporting persons if the stock price rises significantly and they wish to convert more warrants.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock's trading activity.

Key Dates

Keywords

Oncolytics Biotech, Anson Funds, Beneficial Ownership, Schedule 13G, Investment Adviser, Common Stock, Warrants, Biotech, Institutional Ownership